Database→Cagrilintide

Tier 1-2MetabolicWeight LossObesityPREMIUM

Cagrilintide

Cagrilintide (NN0174-0833 / AM833) — Long-Acting Dual Amylin and Calcitonin Receptor Agonist

Not FDA-approved. NDA for CagriSema (cagrilintide plus semaglutide) filed December 2025. Regulatory decision expected approximately October 2026. Cannot legally be used in compounding under current US federal law.

For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use

Profile Overview

Cagrilintide is a once-weekly injectable amylin analogue developed by Novo Nordisk that activates both amylin and calcitonin receptors to produce satiety and reduce food intake. In Phase 3 REDEFINE 1 (n=3,417), cagrilintide combined with semaglutide achieved 20.4% mean body weight loss at 68 weeks versus 3.0% with placebo. Monotherapy produced 11.8% weight loss in the same trial. An NDA for the CagriSema combination was filed with the FDA in December 2025.

🔒

Full Profile: Premium Members Only

The complete Cagrilintide profile includes all use cases with full evidence reviews, mechanism of action deep dive, safety analysis, evidence table, dosing guidance, and stack compatibility data.

For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use